Allergy Therapeutics (AGY) Rating Reiterated by Numis Securities

Allergy Therapeutics (LON:AGY)‘s stock had its “buy” rating reissued by equities researchers at Numis Securities in a research note issued to investors on Tuesday. They presently have a GBX 45 ($0.61) price target on the stock. Numis Securities’ price objective would suggest a potential upside of 58.81% from the stock’s previous close.

Several other brokerages also recently issued reports on AGY. FinnCap reiterated a “buy” rating and issued a GBX 47 ($0.63) price objective on shares of Allergy Therapeutics in a research report on Friday, October 20th. Panmure Gordon reiterated a “buy” rating on shares of Allergy Therapeutics in a research report on Thursday, September 28th.

Shares of Allergy Therapeutics (LON AGY) opened at GBX 28.34 ($0.38) on Tuesday. Allergy Therapeutics has a 1 year low of GBX 19.50 ($0.26) and a 1 year high of GBX 39.50 ($0.53).

In other news, insider Tunde Otulana bought 25,000 shares of the company’s stock in a transaction dated Wednesday, October 11th. The stock was bought at an average price of GBX 51 ($0.69) per share, for a total transaction of £12,750 ($17,160.16).

TRADEMARK VIOLATION NOTICE: “Allergy Therapeutics (AGY) Rating Reiterated by Numis Securities” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at

About Allergy Therapeutics

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with's FREE daily email newsletter.

Leave a Reply